Quantcast

Latest Clinical pharmacology Stories

2014-08-18 16:23:26

LONDON, Aug. 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Impetigo-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278589/-Impetigo-Pipeline-Insights-2014.html SUMMARYDelveInsight's," Impetigo-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Impetigo. This report...

2014-08-18 12:26:58

BETHESDA, Md., Aug. 18, 2014 /PRNewswire/ -- Pinney Associates, Inc. is pleased to welcome Bethea (Annie) Kleykamp, PhD, to our Clinical Pharmacology team. Dr. Kleykamp will be responsible for development of evidence-based literature reviews and other science-based reports on topics including clinical pharmacology, pharmaceutical risk management, abuse potential assessment and abuse deterrent drug products, Rx-to-OTC switch, and consumer health....

2014-08-14 23:01:16

The Firm is representing numerous individuals who allegedly suffered life-threatening cardiovascular injuries prior to the 2012 NaturaLyte and GranuFlo recall. New York, NY (PRWEB) August 14, 2014 A U.S. Food and Drug Administration (FDA) initiative that allows public access to product recall information reveals that actions similar to one that has since prompted thousands of GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) have increased dramatically over the past few years,...

2014-08-11 16:28:42

Tennessee Doctor, Who Survived Substance Abuse, Says Similar Actions in Tennessee Have Saved Lives, Money SANTA MONICA, Calif., Aug. 11, 2014 /PRNewswire-USNewswire/ -- Proposition 46 can save California taxpayers up to $406 million annually by requiring doctors to check California's statewide prescription drug database before prescribing narcotics to first time patients, according to a report released by Consumer Watchdog today. Dr. Stephen Loyd, a recovering prescription drug addict from...

2014-08-11 08:29:12

Meeting with FDA Clarifies Path Forward CASTLE ROCK, Colo., Aug. 11, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients who are at low risk for appendicitis, will host an investor conference call to discuss business updates, including discussion on the progress of...

2014-08-08 08:25:39

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at three upcoming investor events. Details of the three events are as follows: Canaccord 34(th) Annual Growth ConferenceDate: Wednesday August 13(th) Location: Boston,...

2014-08-07 23:10:23

Peterson & Associates is assisting patients who have undergone morcellation during a hysterectomy or fibroid removal review and initiate their legal claims regarding cancer risks. KANSAS CITY, MO (PRWEB) August 07, 2014 Peterson & Associates, P.C., an experienced defective device litigation law firm, is investigating the cancer-risks posed by power morcellators. The firm is concerned about patient safety in light of FDA safety alerts and Johnson & Johnson’s worldwide...

2014-08-07 16:29:15

Conference Call and Webcast scheduled for August 11, 2014, 8:30 a.m. ET CASTLE ROCK, Colo., Aug. 7, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will provide a business update, including discussion on...

2014-08-06 12:29:33

SARASOTA, Fla., Aug. 6, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has made two key independent appointments to the Company's Board of Directors with the recent election of Ms. Lee M. Canaan, CFA and Mr. Edward J. McDonnell, MPH. as new directors. http://photos.prnewswire.com/prnvar/20140806/134113 Both Ms. Canaan and Mr. McDonnell have substantial expertise, experience and knowledge relevant to the Company's mission and...

2014-08-05 16:27:45

Jazz Pharmaceuticals owns worldwide rights to defibrotide DUBLIN, Aug. 5, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of its acquisition of rights to defibrotide in the United States (U.S.) and all other countries in the Americas from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau). Jazz Pharmaceuticals now owns worldwide rights to defibrotide. Defibrotide is a novel product that is marketed by Jazz Pharmaceuticals in the European Union (EU)...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'